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Abstract 
Migraine is a common neurological disorder classified by the World Health Organisation 
(WHO) as one of the top twenty most debilitating diseases in the developed world. Current 
therapies are only effective for a proportion of sufferers and new therapeutic targets are 
desperately needed to alleviate this burden. Recently the role of epigenetics in the 
development of many complex diseases including migraine has become an emerging topic. 
By understanding the importance of acetylation, methylation and other epigenetic 
modifications, it then follows that this modification process is a potential target to manipulate 
epigenetic status with the goal of treating disease. Bisulphite sequencing and methylated 
DNA immunoprecipitation have been used to demonstrate the presence of methylated 
cytosines in the human D-loop of mitochondrial DNA (mtDNA), proving that the mitochondrial 
genome is methylated. For the first time, it has been shown that there is a difference in 
mtDNA epigenetic status between healthy controls and those with disease, especially for 
neurodegenerative and age related conditions. Given co-morbidities with migraine and the 
suggestive link between mitochondrial dysfunction and the lowered threshold for triggering a 
migraine attack, mitochondrial methylation may be a new avenue to pursue. Creative 
thinking and new approaches are needed to solve complex problems and a systems biology 
approach, where multiple layers of information are integrated is becoming more important in 
complex disease modelling. 
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Migraine is a common neurological disorder characterised by severe head pain and an 
assortment of additional symptoms which can include nausea, photophobia, phonophobia 
and for some subtypes of migraine additional neurological symptoms. Migraine is classified 
according to the International Headache Society into two broad categories namely migraine 
without aura (MO) and migraine with aura (MA) [1, 2]. Most patients suffer from MO, with 
only 20% of sufferers experiencing an aura before the onset of a migraine attack. 
Approximately 12% of the Caucasian population suffers from this debilitating disease with 
almost 2/3 of sufferers being female. Migraine is classified by the World Health Organisation 
(WHO) as one of the top twenty most debilitating diseases in the developed world and poses 
a significant personal and economic burden [3].  
 
In 2010 it was estimated that headache disorders in Europe cost an estimated €43.5 billion 
per year [4]. It has been shown that the cost incurred by continuous absenteeism from the 
work place as a result of employees being unable to work due to debilitating migraine 
attacks is actually higher than the direct cost of treatment. Also the total percentage of costs 
attributed to loss of work place productivity caused by chronic disease is by far dominated by 
migraine with 89% attributed to migraine and only 19% for other chronic conditions [5]. 
Current therapies are only effective for a proportion of sufferers and new therapeutic targets 
are desperately needed to alleviate this burden. 
 
Various theories explaining the pathophysiology of migraine have been tested and modified 
for the last eight decades. The most supported current view is that migraine is a complex 
multifactorial disease with both predisposing genetic variance and environmental factors 
contributing to the final phenotype. The actual biological mechanism involved in a migraine 
attack is still debated, but is thought to be caused by activation of the trigeminal nerve 
causing pain sensation in the sensor cortex of the brain and/or a dysfunction of the neuronal 
nuclei located within the brain stem [6].The trigeminal vascular theory states that activation 
of the trigeminal nerve system by a neural, vascular or neurovascular trigger leads to a 
migraine. The trigeminal nerves carry pain signals from the meninges and blood vessels 
infusing the meninges to the trigeminal nucleus in the brain stem which in turn sends signals 
to the sensor cortex via the thalamus. The sensor cortex processes pain signals and other 
senses, thus leading to the sensation of pain experienced during migraine attacks [7]. This 
mechanism is illustrated in Figure 1 below. 
 
Dysfunction of neuronal nuclei can be explained by migraine pain and trigeminovascular 
activation being caused by a central mechanism which may not require a primary sensory 
input [8, 9]. The most recent theory explaining migraine pathogenesis describes migraine as 
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a dysfunction of the subcortical brain structures including the brainstem and diencephalic 
nuclei which are involved in modulating sensory inputs. The theory suggests that aura is 
triggered by dysfunction of these nuclei and that the same mechanism is responsible for the 
pain and other symptoms experienced during migraine attacks [10]. This theory challenges 
the importance of cortical spreading depression (CSD) in generating a migraine attack, a 
process which has previously been emphasized. CSD is a wave of neuronal and glial 
depolarization/ neuronal hyperexcitability followed by a long lasting suppression of neural 
activity [11]. This electrophysiological event has been linked to aura in the human visual 
cortex and is thought to be partly responsible for the sensory and motor disturbances 
experienced during MA attacks.  
 
 
Heritability and Migraine: A Significant Genetic Contribution 
Heritability is the proportion of a trait or disease phenotype which can be attributed to genetic 
variation. The official definition of heritability is the “proportion of phenotypic variation (VP) 
that is due to variation in genetic values (VG).” Genetic values (VG) include the combined 
effect of all loci as well as interactions within (dominance) and between (epistasis) loci. Two 
different basic heritability values can be calculated namely broad-sense and narrow-sense 
heritability. Broad-sense heritability, or H2 is defined as the proportion of phenotypic variation 
due to genetic values which include effects of dominance and epistasis (H2 = VG/VP) while 
narrow-sense heritability only considers genetic variation due to additive genetic values (h2 = 
VA/VP ) [12].  
For human diseases and other complex traits, heritability can be estimated from the 
concordance rate between monozygotic and dizygotic twins [13]. More complex models 
which examine the correlation of offspring and parental phenotypes can be used to estimate 
heritability via complex statistical methods. These are employed when phenotypic measures 
are available on individuals with a mixture of relationships, both within and across multiple 
generations, or when there are unequal numbers of observations per family [14]. A number 
of twin studies in migraine have shown that the heritability of migraine ranges from 40-60% 
and that the contribution of non-shared environmental factors is 35-55% [15-17]. Based on 
this information it is clear that both genetic factors and environment play an approximately 
equally important role in the pathogenicity of migraine.  
Previously, much emphasis has been placed on genetic studies and conducting large 
Genome Wide Association Study (GWAS) experiments, but with the knowledge that 
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environmental factors may directly trigger migraine attacks, more inclusive models which 
take into account environmental factors are needed [18]. One approach which could be used 
to be more inclusive of environmental effects is to take into account epigenetic markers 
which are known to change in response to changing environmental factors. Recent research 
has shown that there is a direct correlation between CSD and changes in epigenetic markers 
in genes involved in neuronal plasticity [19]. This is some of the first evidence to suggest that 
epigenetics could play an important role in migraine pathogenicity [20]. 
Epigenetics 
Epigenetics refers to partially heritable alterations which influence gene expression, not due 
to changes in DNA sequence but rather as a result of higher structural modifications. There 
are three main systems involved in epigenetic structuring namely; methylation, histone 
modification and RNA-associated silencing [21]. It is well known that epigenetics plays a 
crucial role in gene regulation, growth and especially in development [22]. Any alterations in 
epigenetic state may result in inappropriate expression or silencing of genes and 
consequently lead to a myriad of downstream problems. These alterations are often 
chemical additions or removals of methyl or acetyl groups that result in a change to the 
chromatin conformation and consequently a change in gene expression. Alterations can be 
caused by either environmental factors or trigged by ageing processes. Research has shown 
that epigenetics plays a crucial role in the development of many cancers, but more recently 
the role of epigenetics in the development of other complex diseases including migraine has 
become an emerging topic [20, 23].  
Methylation 
Methylation is the main form of epigenetic modification and occurs by the addition of a 
methyl group to the 5’ Cytosine of CpG groups. This chemical reaction is initiated and 
maintained by DNA methyl transferases. The addition of methyl groups promotes a closed 
chromatin conformation and prevents transcription from taking place. The mechanistic action 
blocking the binding of transcription factors and other regulatory sequences such as 
enhancers occurs through the recruitment of MECP2 proteins which bind to methylated 
cytosines and attract histone deacetylases (HDACs). HDACs in turn function to promote a 
closed chromatin formation. This closed conformation also prevents the transcriptome, a 
critical complex involved in DNA polymerase binding, from associating with the promoter site 
which further down regulates transcription.  In this way methylation in conjunction with other 
intricate pathways partly controls gene expression [24-26].  
Histone Modifications 
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Histones form the basis of chromatin modelling, a process which is intricately linked with 
gene regulation. Chemical modifications which alter histone structure include acetylation, 
ubiquination, phosphorylation, sumoylation and methylation. Acetylation occurs when the H 
atoms of the free amino group on particular lysine residues at the N terminus of histone 
molecules are substituted with acetyl groups, thus reducing the positive charge of the 
histone and allowing the chromatin to unwind. DNA is negatively charged due to the 
phosphate group constituting the phosphate backbone and therefore when in close proximity 
to positively charged histones, the DNA is strongly attracted to the charge and is kept in a 
tight conformation. The reduction of this positive charge by the addition of acetyl groups 
allows the DNA to take on a looser conformation and thus makes it more accessible to 
transcription [27]. 
 
 These reactions are catalysed by histone acetyl transferase enzymes. Activators and 
inhibitors are also known to be involved in gene regulation by manipulating these chemical 
reactions. Histones can be acetylated by activators promoting chromatin structure from a 
closed to an open configuration. The reverse can occur where inhibitors direct deacetylation 
of histones with the opposite effect. 
Ubiquitination is another type of chemical modification that can alter histone structure. 
Ubiquitin, a small protein consisting of 76 amino acids forms an internal branched chain with 
lysine of histone 2A in position 119. This reduces the positive charge of the histone, which 
promotes a more open conformation and allows more transcription to take place. 
Phosphorylation is yet another modification which produces an open chromatin structure and 
allows transcription to take place. The negative charges of the phosphate groups make the 
histones less positive, and repel the negatively charged DNA [28].  
 
 Combinations of chemical changes can also affect chromatin structure such as 
phosphorylation of histone residue H3 on serine 10 which promotes acetylation on the 
adjacent lysine 14 residue. Demethylation of lysine 9 is accompanied by phosphorylation of 
serine 10 and acetylation of lysine 14 which produces an open chromatin conformation. All 
of these modifications play a major role in genome regulation and are important for normal 
cellular functions like X chromosome inactivation and genomic imprinting. It has been 
contemplated that a histone code exists which can be read and interpreted by different 
cellular factors. Recent research is placing more emphasis on the role that these processes 
play not just in normal cell functioning, but also in the development of complex diseases [20, 
27, 29]. 
 
RNA Associated Silencing 
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It has been experimentally proven that transcription is widespread throughout the genome 
and is many fold higher than originally predicted. It is now clear that non-coding transcripts 
are abundant throughout many cell types and that they play an essential role in gene 
regulation. Non-coding RNAs are divided into several sub-classes and have been associated 
with important functions, most of which are regulatory in nature. Functions which have been 
associated with ncRNAs include transcriptional activation, gene silencing, imprinting, dosage 
compensation, translational silencing, modulation of protein function and binding as 
riboswitches to regulatory metabolites. More specifically it has been well established that 
anti-sense RNAs can bind to complementary regions in the genome, mediating RNA 
degradation and effectively silencing gene expression. RNA associated silencing and the 
role that this regulatory mechanism plays in disease is becoming an important research 
focus [30, 31]. 
Epigenetic therapy 
 
The initial thinking behind developing epigenetic therapies is that if it is possible to 
chemically manipulate factors such as methylation, acetylation etc., then it may be possible 
to alter regions where aberrant changes have taken place in order to try and restore the 
original state. Many agents capable of altering both methylation and acetylation have been 
discovered, and the applications of these are currently being tested [21]. Agents include 5-
azatine, 5-aza-2-deoxycytidine, procainamide, and tea extracts. The compounds 5-azacytine 
and 5-aza-2-deoxycytidine were initially used as cytotoxic agents, but their dual functionality 
has since been exploited by use in inhibition of methylation [32]. By inhibiting methylation in 
regions where aberrant hypermethylation has occurred, appropriate gene expression may be 
restored [33]. The mechanism by which this happens is the conversion of nucleoside 
analogues to deoxynucleotide triphosphates which are substituted into replicating DNA in 
place of cytosine. DNA methyltransferases get trapped on DNA containing modified bases 
such as azacytosine, 5-fluorocytosine, pseudoisocytosine or zebularine, resulting in the 
formation of heritably demethylated DNA. 
 
Targeting epigenetic mechanisms other than methylation could also be an avenue to 
pursuing novel drug targets. By understanding the importance of acetylation in epigenetic 
modification, it then follows that this modification process is also a good target to manipulate 
epigenetic status. The association between silencing and histone deacetylation, which is 
catalysed by histone deacetylases (HDACs), has been well established. A growing number 
of small molecules have been designed to inhibit HDACs and thereby activate gene 
expression in regions where aberrant silencing has taken place.  
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An immediate and logical potential problem associated with taking such an approach is the 
cytotoxic properties of the above mentioned compounds. However clinical trials indicate that 
low doses of these compounds may procure benefits which far surpass any cytotoxic effects. 
A new trial has shown that myeloid dysplastic syndrome and other leukaemias can be 
somewhat effectively treated using this approach [34]. It may even be possible to make use 
of tea and sponge extracts in place of harsh chemicals to reverse methylation [35]. Current 
trials are underway to test the efficacy of such compounds.  
 
Different HDAC inhibitors are being used intravenously or orally in several phase I and II 
cancer clinical trials, in which changes in histone acetylation have been documented. 
Depending on the outcomes of this research, it may be that epigenetic therapy could 
become the novel therapeutic so desperately needed for the treatment of many complex 
diseases, including migraine. However some caution must also be used with these 
approaches as treatment must be specific to the target gene region. Global demethylation 
would be far more detrimental than any benefits of treatment. It will therefore be important in 
the future to design therapies which can target individual enzymes/ genes and thus increase 
the precision of this type of approach. Despite the promise of miracles, there remains much 
work to be done before epigenetic therapies can become mainstream treatment plans [21, 
36]. 
 
Mitochondrial Dysfunction and Migraine 
Rationale for investigation 
Several lines of evidence exist to suggest that mitochondrial dysfunction may contribute to 
the pathogenesis of at least some subtypes of migraine. Brain and muscle are highly 
dependent on oxidative metabolism and are therefore the most severely affected tissues in 
the mitochondrial disorders. A variety of morphological, biochemical, imaging and genetic 
studies have provided evidence that mitochondrial dysfunction may play a role in migraine 
susceptibility [37]. A previously published comprehensive review article describes a plausible 
role of mitochondrial dysfunction in migraine susceptibility based on biochemical, 
physiological and limited genetic studies that have already been conducted [38]. 
Mitochondrial DNA does not undergo recombination and is inherited exclusively along the 
maternal lineage as shown in Figure 2, therefore any changes that occur in the DNA 
sequence can be tracked through multiple generations. This clear mode of inheritance has 
aided researchers in identifying causal variants involved in mitochondrial disorders through 
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family linkage studies [39]. Migraine occurs in three times more female cases compared to 
males, suggesting that either an X-linked form of inheritance could be involved or that 
mitochondrial transmission occurs in some families [40]. By examining mitochondrial 
variation in a large family pedigree a correlation may be found between mitochondrial 
variants and migraine thus identifying true casual variants. The preponderance of female 
migraine sufferers presents a strong case for investigating the mitochondrial genome.  
One of the largest groups of mitochondrial disorders and perhaps the most comprehensively 
defined are the mitochondrial myopathies and ecephalomyopathies. Some of the most 
common syndromes are listed in Table 1 below. The mitochondrial myopathies comprise 
those diseases which cause muscle weakness and wasting with severity ranging from 
progressive weakening to death [41]. As mentioned previously muscle and neural tissues 
are the most sensitive to mitochondrial dysfunction. The combined effects of energy 
shortage and toxin accumulation give rise to many of the symptoms of mitochondrial 
mypotahies which include muscle weakness, exercise intolerance, heart failure, movement 
disorders and droopy eyelids [42].  
Mitochondrial encephalomyopathies include a myopathy component in addition to a 
neurological aspect to the disease. The neurological symptoms represent a significant 
overlap with those experienced by migraine sufferers including hearing impairment, 
migraine-like headaches, seizures and in severe cases stroke like episodes [43]. This 
suggests that migraine and some of the myopathies may share a significant co-morbidity, 
strengthening the rationale to investigate mitochondrial variants in relation to migraine 
susceptibility. Furthermore, research has shown that there is an association between 
epigenetic changes and all the comorbid migraine disorders, suggesting that epigenetics 
could play an important role in migraine pathogenesis [44, 45]. This relationship brings into 
question the idea of mitochondrial epigenetics and the role that it could play in migraine. 
It is well known that the brain needs a continuous and sufficient supply of energy in the form 
of ATP in order to function efficiently. It is therefore highly feasible that any interruption in 
energy production could result in neuronal dysfunction and lower the threshold for initiation 
of a migraine attack. The majority of the body’s energy supply is produced via the oxidative 
phosphorylation pathway or the electron transport chain which is contained within the 
mitochondria [46]. Any disruption in mitochondrial function which adversely affects the 
production of energy is likely to affect the tissues which are most heavily reliant on a 
sufficient source of energy and in some cases cause a pathological state.  To date very few 
migraine studies have examined the association between mitochondrial variation and 
migraine susceptibility, making this an area which sorely needs to be addressed. 
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A reduction in oxidative phosphorylative activity can cause other severe neurological 
diseases later on in life, a process which is likely linked to aging and an increase in reactive 
oxygen species over time. Alzheimer’s and Parkinson’s disease affect many elderly people 
worldwide with devastating phenotypic characteristics. The risk of developing this disease is 
much greater if the proband has an affected mother, thus strengthening the hypothesis that 
mitochondrial dysfunction plays a role in susceptibility [41, 47]. Other common diseases that 
mtDNA variants have been associated with include cancer, diabetes, stroke, 
cardiomyopathy, mental retardation, migraine and male infertility [48]. 
Mitochondrial variants and other complex interactions 
Most complex mitochondrial diseases involve nuclear encoded genes in addition to 
mitochondrial variants. Despite the fact that the mitochondrial genome encodes for so few 
proteins, thousands of proteins are still found within the mitochondria. The rest of the 
proteins are encoded by the nuclear genome and are transported into the mitochondria via 
membrane receptor proteins. MitoProteome is a database which records all known nuclear 
encoded mitochondrial proteins and is curated on an ongoing basis. Currently 780 known 
nuclear encoded mitochondrial proteins are listed, with an additional 492 listed as putative 
mitochondrial proteins [49, 50]. These 1000+ proteins are targeted to the mitochondria and 
sorted to the different mitochondrial subcompartments following translocation through the 
mitochondrial membranes. Separate translocases in the outer (TOM complex) and inner 
(TIM complex) membrane assist in identifying preproteins and concurrently transporting 
them across the two membranes. Factors in the cytosol as well as molecular chaperones in 
the matrix assist in this process  as shown in Figure 3 [51].  
New evidence suggests that regulators of gene expression including miRNAs are also 
imported into the mitochondria. A recent study showed that miRNAs which are already 
known to be transcribed within the nucleus and undergo processing and maturation in the 
cytosol, also localise to the mitochondria. The study found 13 miRNAs to be significantly 
enriched in the mitochondria and the authors hypothesize that post-transcriptional regulation 
via miRNAs could be a plausible mechanism to alter expression in response to metabolic 
conditions of the cell [52]. Two of the miRNAs namely miR-1974 and miR-1977 mapped to 
the mitochondrial tRNA and rRNA genes, suggesting that not all mitochondrial miRNAs 
originate from the nucleus. As is the case for proteins, it is likely that a combination of 
mitochondrial and nuclear genes are involved in the production of miRNAs which are 
involved in regulation of mitochondrial function.  
Migraine can show variable expressivity with different levels of penetrance, even within the 
same family. This is due to the complex nature of the disease and multiple levels of variation 
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involved in cell functioning which affect the final phenotype. Some of the variable 
expressivity can be explained by heteroplasmy. Heteroplasmy is the state of having two 
variant mtDNA populations within a cell and depending on the levels of heteroplasmy and 
also the tissue type the disease phenotype can be masked [53]. It is also possible that 
epigenetic changes could add another layer of complexity to migraine. In order to 
comprehensively investigate the underlying genetic causes of migraine it is necessary to 
measure any epigenetic changes occurring in the nuclear DNA in addition the mitochondrial 
genome. 
 
Mitochondrial Methylation 
Research interests in the relationship between nuclear DNA methylation, environmental 
exposures and disease outcome are well established. Epigenetic profiling has already 
become integrated into clinical practise for early diagnosis of cancer and as a molecular tool 
for determining cancer stages [54, 55]. Bisulphite sequencing and methylated DNA 
immunoprecipitation in peripheral blood have been used to demonstrate the presence of 
methylated cytosines in the human D-loop of mtDNA, proving that the mitochondrial genome 
is methylated. For the first time, it has been shown that there is a difference in mtDNA 
epigenetic status between healthy controls and those with disease, especially for 
neurodegenerative and age related conditions [56-58]. Changes in the level of 5-methyl 
cytosine have been detected in mitochondria isolated from neurons of patients with 
amyotrophic lateral sclerosis (ALS) compared to healthy controls [59]. While still remaining 
to be investigated it has been suggested that mtDNA methylation could play an important 
role in the etiology of Alzheimer’s disease, Parkinson’s disease and dementia [58, 60]. It 
may not be such a stretch of the imagination then to conclude that investigating 
mitochondrial methylation in relation to migraine could be a novel and useful avenue. 
 
A Multi-layered Approach 
For complex diseases where both a genetic and environmental component play an integral 
role in pathogenesis, it is becoming more important to develop models which factor in both of 
these components. Epigenetic changes which are so heavily influenced by the environment 
have been intricately studied in the nuclear genome. Recent evidence directly suggests a 
link between nuclear epigenetic changes and migraine and indirectly suggests that the 
emerging field of mitochondrial methylation could provide a piece of the answer for the 
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complex question; what causes migraine. The systems biology approach, where multiple 
layers of information are integrated is becoming more important in complex disease 
modelling. Merging genomic, epigenetic, transcriptomic, proteomic and metabalomic data in 
order to provide a complete model is becoming a focus in biomedical research. Creative 
thinking and new approaches are needed to develop better treatment strategies for diseases 
such as migraine which have such a profound personal and economic impact.  
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Tables  
 
Table  1. Summary of the common mitochondrial myopathies and 
encephalomyopathies 
Disease Abbreviatio
n 
Confirmed 
Causative 
Mutations 
Reference 
Kearns-Sayre syndrome KSS 5kb deletion, 
G12315A 
[61, 62] 
Leigh syndrome LS A3243G, 
A5537insT, 
G8363A 
[63-65] 
Mitochondrial 
encephalomyopathy, lactic 
acidosis and stroke like 
episodes 
MELAS G583A, A3243G, 
C3256T, T3271C, 
T3291C, 
G4332A, 
G12147A 
[63, 66-72] 
Myoclonus epilepsy with 
ragged red fibres 
MERRF A8344G, 
T8356C, 
G8363A, 
G12147A 
[72-75] 
Nueropathy, ataxia and 
retinitis pigmentosa 
NARP 8993G/C [76] 
Progressive external 
opthalmoplegia 
PEO A3243G, 
G4298A, 
G4308A, 
G5703A, 
G12315A 
[62, 77-80] 
Leber hereditary optic 
neuropathy 
LHON 11778 A, 
14484C, 14459A, 
3460A 
[81] 
Deafness DEAF C1494T, 
A1555G, G8363A 
[82-84] 
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Figure 1: Upon activation of the trigeminal nerve, pain signals are carried to the 
trigeminal nucleus and then to the sensor cortex via the thalamus 
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Figure2: Mode of inheritance for mitochondrial DNA 
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Figure 3: Illustration of the TOM Complex involved in import of nuclear encoded 
proteins into the mitochondria. Adapted from [51] 
 
 
 
 
